Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single‐center experience of eight patients
Abstract Recurrent respiratory papillomatosis (RRP) is a human papilloma virus (HPV)‐driven benign neoplasm, affecting larynx, trachea, and even lung, leading to voice disorders, airway obstruction, and postobstructive pneumonia. Several case reports have documented the promising efficacy of intrave...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Laryngoscope Investigative Otolaryngology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/lio2.1013 |
| _version_ | 1797843587554082816 |
|---|---|
| author | Zengjun Liu Yang Xiao Jing Xu Mengyao Liu Mingyong Han Wenyu Hu Dongyuan Zhu |
| author_facet | Zengjun Liu Yang Xiao Jing Xu Mengyao Liu Mingyong Han Wenyu Hu Dongyuan Zhu |
| author_sort | Zengjun Liu |
| collection | DOAJ |
| description | Abstract Recurrent respiratory papillomatosis (RRP) is a human papilloma virus (HPV)‐driven benign neoplasm, affecting larynx, trachea, and even lung, leading to voice disorders, airway obstruction, and postobstructive pneumonia. Several case reports have documented the promising efficacy of intravenous bevacizumab in reducing the need for surgical intervention among RRP patients. Herein, we present our experience on systemic bevacizumab for pediatric patients with aggressive RRP. Methods We retrospectively analyzed clinical, laboratory, radiological, and bronchoscopy findings of pediatric patients with aggressive RRP treated with systemic bevacizumab from July 26, 2021 to March 1, 2022. Results Eight consecutive patients were included. Median age at treatment initiation was 5.5 (range 2.5–8) years old. Twenty‐five percentage (2/8) of patients experienced tracheotomy. Pulmonary papilloma was present in 62.5% (5/8) patients. Patients received median 10 cycles of bevacizumab (range 5–12). Patients received initial dosing of 4–7.5 mg/kg every 2–10 weeks of bevacizumab and subsequently extended after achieving the maximum response. None of the patients required surgical intervention during a median 10 (range 8.2–15.4) months follow‐up after initiating bevacizumab treatment. Both patients with evaluable lung lesions showed objective response. Only Grade 1 abdominal pain and Grade 1 hyperuricemia were recorded. Conclusion Systemic bevacizumab seems to be a well‐tolerated and effective treatment option for pediatric patients with aggressive RRP. |
| first_indexed | 2024-04-09T17:07:10Z |
| format | Article |
| id | doaj.art-998b386c891f41d391232eb6ff06243a |
| institution | Directory Open Access Journal |
| issn | 2378-8038 |
| language | English |
| last_indexed | 2024-04-09T17:07:10Z |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Laryngoscope Investigative Otolaryngology |
| spelling | doaj.art-998b386c891f41d391232eb6ff06243a2023-04-20T11:45:42ZengWileyLaryngoscope Investigative Otolaryngology2378-80382023-04-018243544010.1002/lio2.1013Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single‐center experience of eight patientsZengjun Liu0Yang Xiao1Jing Xu2Mengyao Liu3Mingyong Han4Wenyu Hu5Dongyuan Zhu6Tumor Research and Therapy Center, Shandong Provincial Hospital Shandong University Jinan Shandong ChinaDepartment of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital Capital Medical University Beijing ChinaRare tumors Department, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong ChinaRare tumors Department, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong ChinaTumor Research and Therapy Center, Shandong Provincial Hospital Shandong University Jinan Shandong ChinaRare tumors Department, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong ChinaRare tumors Department, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong ChinaAbstract Recurrent respiratory papillomatosis (RRP) is a human papilloma virus (HPV)‐driven benign neoplasm, affecting larynx, trachea, and even lung, leading to voice disorders, airway obstruction, and postobstructive pneumonia. Several case reports have documented the promising efficacy of intravenous bevacizumab in reducing the need for surgical intervention among RRP patients. Herein, we present our experience on systemic bevacizumab for pediatric patients with aggressive RRP. Methods We retrospectively analyzed clinical, laboratory, radiological, and bronchoscopy findings of pediatric patients with aggressive RRP treated with systemic bevacizumab from July 26, 2021 to March 1, 2022. Results Eight consecutive patients were included. Median age at treatment initiation was 5.5 (range 2.5–8) years old. Twenty‐five percentage (2/8) of patients experienced tracheotomy. Pulmonary papilloma was present in 62.5% (5/8) patients. Patients received median 10 cycles of bevacizumab (range 5–12). Patients received initial dosing of 4–7.5 mg/kg every 2–10 weeks of bevacizumab and subsequently extended after achieving the maximum response. None of the patients required surgical intervention during a median 10 (range 8.2–15.4) months follow‐up after initiating bevacizumab treatment. Both patients with evaluable lung lesions showed objective response. Only Grade 1 abdominal pain and Grade 1 hyperuricemia were recorded. Conclusion Systemic bevacizumab seems to be a well‐tolerated and effective treatment option for pediatric patients with aggressive RRP.https://doi.org/10.1002/lio2.1013bevacizumabefficacypediatricsrecurrent respiratory papillomatosissafety |
| spellingShingle | Zengjun Liu Yang Xiao Jing Xu Mengyao Liu Mingyong Han Wenyu Hu Dongyuan Zhu Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single‐center experience of eight patients Laryngoscope Investigative Otolaryngology bevacizumab efficacy pediatrics recurrent respiratory papillomatosis safety |
| title | Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single‐center experience of eight patients |
| title_full | Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single‐center experience of eight patients |
| title_fullStr | Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single‐center experience of eight patients |
| title_full_unstemmed | Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single‐center experience of eight patients |
| title_short | Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single‐center experience of eight patients |
| title_sort | systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis one single center experience of eight patients |
| topic | bevacizumab efficacy pediatrics recurrent respiratory papillomatosis safety |
| url | https://doi.org/10.1002/lio2.1013 |
| work_keys_str_mv | AT zengjunliu systemicbevacizumabforpediatricpatientswithaggressiverecurrentrespiratorypapillomatosisonesinglecenterexperienceofeightpatients AT yangxiao systemicbevacizumabforpediatricpatientswithaggressiverecurrentrespiratorypapillomatosisonesinglecenterexperienceofeightpatients AT jingxu systemicbevacizumabforpediatricpatientswithaggressiverecurrentrespiratorypapillomatosisonesinglecenterexperienceofeightpatients AT mengyaoliu systemicbevacizumabforpediatricpatientswithaggressiverecurrentrespiratorypapillomatosisonesinglecenterexperienceofeightpatients AT mingyonghan systemicbevacizumabforpediatricpatientswithaggressiverecurrentrespiratorypapillomatosisonesinglecenterexperienceofeightpatients AT wenyuhu systemicbevacizumabforpediatricpatientswithaggressiverecurrentrespiratorypapillomatosisonesinglecenterexperienceofeightpatients AT dongyuanzhu systemicbevacizumabforpediatricpatientswithaggressiverecurrentrespiratorypapillomatosisonesinglecenterexperienceofeightpatients |